[Blinatumomab (ALL, MRD-positive patients) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018003542
German
Original Title:
Blinatumomab (akute lymphatische Leukaemie: Erwachsene mit minimaler Resterkrankung)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/g19-08.html
Year Published:
2019
URL for published report:
https://www.iqwig.de/download/G19-08_Blinatumomab_ALL-Erwachsene-mit-minimaler-Resterkrankung_Bewertung-35a-Absatz-1-Satz-11-SGB-V_V1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- Antibodies, Bispecific
- Antineoplastic Agents
Keywords
- Blinatumomab
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- Health Care Costs
- Epidemiology
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.